MA45053A - Polynucléotides codant pour un régulateur de conductance transmembranaire de fibrose kystique pour le traitement de la fibrose kystique - Google Patents
Polynucléotides codant pour un régulateur de conductance transmembranaire de fibrose kystique pour le traitement de la fibrose kystiqueInfo
- Publication number
- MA45053A MA45053A MA045053A MA45053A MA45053A MA 45053 A MA45053 A MA 45053A MA 045053 A MA045053 A MA 045053A MA 45053 A MA45053 A MA 45053A MA 45053 A MA45053 A MA 45053A
- Authority
- MA
- Morocco
- Prior art keywords
- cystic fibrosis
- treatment
- conductance regulator
- transmembrane conductance
- polynucleotides coding
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/04—Phosphotransferases with a phosphate group as acceptor (2.7.4)
- C12Y207/04003—Adenylate kinase (2.7.4.3)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662338492P | 2016-05-18 | 2016-05-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA45053A true MA45053A (fr) | 2019-03-27 |
Family
ID=60325676
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA045053A MA45053A (fr) | 2016-05-18 | 2017-05-18 | Polynucléotides codant pour un régulateur de conductance transmembranaire de fibrose kystique pour le traitement de la fibrose kystique |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US11801227B2 (fr) |
| EP (1) | EP3458108A4 (fr) |
| MA (1) | MA45053A (fr) |
| WO (1) | WO2017201347A1 (fr) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| AU2014329452B2 (en) | 2013-10-03 | 2019-06-20 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| CA2935960C (fr) | 2014-01-08 | 2023-01-10 | Bart Lipkens | Dispositif d'acoustophorese avec double chambre acoustophoretique |
| CN106659803A (zh) | 2014-04-23 | 2017-05-10 | 摩登纳特斯有限公司 | 核酸疫苗 |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
| US11007260B2 (en) | 2015-07-21 | 2021-05-18 | Modernatx, Inc. | Infectious disease vaccines |
| WO2017031232A1 (fr) | 2015-08-17 | 2017-02-23 | Modernatx, Inc. | Procédés de préparation de particules et compositions associées |
| HUE057613T2 (hu) | 2015-09-17 | 2022-05-28 | Modernatx Inc | Vegyületek és készítmények terápiás szerek intracelluláris bejuttatására |
| JP2018531290A (ja) | 2015-10-22 | 2018-10-25 | モデルナティーエックス， インコーポレイテッド | 性感染症ワクチン |
| SG11201803360UA (en) | 2015-10-22 | 2018-05-30 | Modernatx Inc | Nucleic acid vaccines for varicella zoster virus (vzv) |
| WO2017070624A1 (fr) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Vaccins contre des maladies tropicales |
| CA3002922A1 (fr) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Vaccin contre le cytomegalovirus humain |
| RS63381B1 (sr) | 2015-10-22 | 2022-08-31 | Modernatx Inc | Vakcine protiv respiratornih virusa |
| AU2016366978B2 (en) | 2015-12-10 | 2022-07-28 | Modernatx, Inc. | Compositions and methods for delivery of therapeutic agents |
| JP7065036B2 (ja) | 2015-12-17 | 2022-05-11 | モダーナティエックス・インコーポレイテッド | メチルマロニルＣｏＡムターゼをコードするポリヌクレオチド |
| DK3394030T3 (da) | 2015-12-22 | 2022-03-28 | Modernatx Inc | Forbindelser og sammensætninger til intracellulær afgivelse af midler |
| US10465190B1 (en) | 2015-12-23 | 2019-11-05 | Modernatx, Inc. | In vitro transcription methods and constructs |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| US10993918B2 (en) | 2016-05-18 | 2021-05-04 | Modernatx, Inc. | Polynucleotides encoding citrin for the treatment of Citrullinemia type 2 |
| EP3458105B1 (fr) | 2016-05-18 | 2024-01-17 | Modernatx, Inc. | Polynucléotides codant pour la galactose-1-phosphate uridylyltransférase destinés au traitement de la galactosémie de type 1 |
| CN109640962B (zh) | 2016-05-18 | 2022-07-19 | 摩登纳特斯有限公司 | 编码松弛素的多核苷酸 |
| ES2928475T3 (es) | 2016-09-14 | 2022-11-18 | Modernatx Inc | Composiciones de ARN de alta pureza y métodos para su preparación |
| WO2018075980A1 (fr) | 2016-10-21 | 2018-04-26 | Modernatx, Inc. | Vaccin contre le cytomégalovirus humain |
| US11583504B2 (en) | 2016-11-08 | 2023-02-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| CN110167587A (zh) | 2016-11-11 | 2019-08-23 | 摩登纳特斯有限公司 | 流感疫苗 |
| EP3551193A4 (fr) | 2016-12-08 | 2020-08-19 | Modernatx, Inc. | Vaccins à acide nucléique contre des virus respiratoires |
| US11384352B2 (en) | 2016-12-13 | 2022-07-12 | Modernatx, Inc. | RNA affinity purification |
| MA47515A (fr) | 2017-02-16 | 2019-12-25 | Modernatx Inc | Compositions immunogènes très puissantes |
| EP3596042B1 (fr) | 2017-03-15 | 2022-01-12 | Modernatx, Inc. | Formes cristallines d'aminolipides |
| PL3596041T3 (pl) | 2017-03-15 | 2023-03-06 | Modernatx, Inc. | Związek i kompozycje do dokomórkowego dostarczania środków terapeutycznych |
| US11576961B2 (en) | 2017-03-15 | 2023-02-14 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| US11752206B2 (en) | 2017-03-15 | 2023-09-12 | Modernatx, Inc. | Herpes simplex virus vaccine |
| WO2018170270A1 (fr) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Vaccin contre le virus varicelle-zona |
| WO2018170260A1 (fr) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Vaccin contre le virus respiratoire syncytial |
| WO2018170347A1 (fr) | 2017-03-17 | 2018-09-20 | Modernatx, Inc. | Vaccins à base d'arn contre des maladies zoonotiques |
| CA3050616A1 (fr) | 2017-03-24 | 2018-09-27 | Curevac Ag | Acides nucleiques codant pour des proteines associees a crispr et leurs utilisations |
| WO2018187590A1 (fr) | 2017-04-05 | 2018-10-11 | Modernatx, Inc. | Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée |
| EP3638215A4 (fr) | 2017-06-15 | 2021-03-24 | Modernatx, Inc. | Formulations d'arn |
| EP3668971B1 (fr) | 2017-08-18 | 2024-04-10 | ModernaTX, Inc. | Variants d'arn polymérase |
| US11866696B2 (en) | 2017-08-18 | 2024-01-09 | Modernatx, Inc. | Analytical HPLC methods |
| WO2019036685A1 (fr) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | Procédés pour analyse par clhp |
| JP7275111B2 (ja) | 2017-08-31 | 2023-05-17 | モデルナティエックス インコーポレイテッド | 脂質ナノ粒子の生成方法 |
| WO2019055807A1 (fr) | 2017-09-14 | 2019-03-21 | Modernatx, Inc. | Vaccins à arn contre le virus zika |
| AU2018385759B2 (en) | 2017-12-14 | 2021-10-21 | Flodesign Sonics, Inc. | Acoustic transducer driver and controller |
| EP3746090A4 (fr) | 2018-01-29 | 2021-11-17 | ModernaTX, Inc. | Vaccins à base d'arn contre le vrs |
| CN113454105A (zh) | 2019-02-08 | 2021-09-28 | 克里斯托生物技术股份有限公司 | 用于递送cftr多肽的组合物和方法 |
| US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
| CA3130888A1 (fr) | 2019-02-20 | 2020-08-27 | Modernatx, Inc. | Variants d'arn polymerase pour le coiffage co-transcriptionnel |
| US11851694B1 (en) | 2019-02-20 | 2023-12-26 | Modernatx, Inc. | High fidelity in vitro transcription |
| CA3154618A1 (fr) | 2019-09-19 | 2021-03-25 | Modernatx, Inc. | Composes lipidiques de queue ramifies et compositions pour l'administration intracellulaire d'agents therapeutiques |
| EP4132576A1 (fr) | 2020-04-09 | 2023-02-15 | Suzhou Abogen Biosciences Co., Ltd. | Vaccins à base d'acide nucléique pour coronavirus |
| WO2021204175A1 (fr) | 2020-04-09 | 2021-10-14 | Suzhou Abogen Biosciences Co., Ltd. | Compositions de nanoparticules lipidiques |
| IL297419A (en) | 2020-04-22 | 2022-12-01 | BioNTech SE | Vaccine against the corona virus |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| WO2022104131A1 (fr) * | 2020-11-13 | 2022-05-19 | Modernatx, Inc. | Polynucléotides codant pour un régulateur de conductance transmembranaire de la mucoviscidose pour le traitement de la mucoviscidose |
| US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
| WO2022212766A2 (fr) * | 2021-03-31 | 2022-10-06 | Hunterian Medicine Llc | Promoteurs compacts pour l'expression génique |
| WO2024002985A1 (fr) | 2022-06-26 | 2024-01-04 | BioNTech SE | Vaccin contre le coronavirus |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2937245T3 (es) * | 2005-08-23 | 2023-03-27 | Univ Pennsylvania | ARN que contiene nucleósidos modificados y métodos de uso del mismo |
| CA2665620A1 (fr) | 2006-10-12 | 2008-04-17 | Copernicus Therapeutics Inc. | Cftr a optimisation par codon |
| WO2009030254A1 (fr) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes d'arn et de peptides cationiques pour transfection et immunostimulation |
| ES2713852T3 (es) | 2009-12-01 | 2019-05-24 | Translate Bio Inc | Derivado de esteroides para la administración de ARNm en enfermedades genéticas humanas |
| EP2694660B1 (fr) | 2011-04-03 | 2018-08-08 | The General Hospital Corporation | Expression protéique efficace in vivo à l'aide d'arn modifié (mod-arn) |
| KR20200084048A (ko) * | 2011-06-08 | 2020-07-09 | 샤이어 휴먼 지네틱 테라피즈 인크. | Mrna 전달을 위한 지질 나노입자 조성물 및 방법 |
| CA2838063C (fr) | 2011-06-08 | 2023-07-11 | Shire Human Genetic Therapies, Inc. | Lipides clivables |
| WO2013086373A1 (fr) | 2011-12-07 | 2013-06-13 | Alnylam Pharmaceuticals, Inc. | Lipides pour l'administration d'agents actifs |
| NZ715957A (en) | 2012-02-07 | 2017-08-25 | Global Bio Therapeutics Inc | Compartmentalized method of nucleic acid delivery and compositions and uses thereof |
| US9877919B2 (en) | 2012-03-29 | 2018-01-30 | Translate Bio, Inc. | Lipid-derived neutral nanoparticles |
| US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| JP2015516143A (ja) | 2012-04-02 | 2015-06-08 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | ヒト疾患に関連するタンパク質の産生のための修飾ポリヌクレオチド |
| US20140275229A1 (en) | 2012-04-02 | 2014-09-18 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding udp glucuronosyltransferase 1 family, polypeptide a1 |
| JP2015518705A (ja) | 2012-04-02 | 2015-07-06 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | ヒト疾患に関連する生物製剤およびタンパク質の産生のための修飾ポリヌクレオチド |
| EP3884949A1 (fr) | 2012-06-08 | 2021-09-29 | Translate Bio, Inc. | Administration pulmonaire d'arnm à des cellules cibles autres que pulmonaires |
| WO2013182683A1 (fr) | 2012-06-08 | 2013-12-12 | Ethris Gmbh | Administration pulmonaire d'un arn messager |
| LT2922554T (lt) | 2012-11-26 | 2022-06-27 | Modernatx, Inc. | Terminaliai modifikuota rnr |
| KR20210122917A (ko) * | 2013-03-14 | 2021-10-12 | 샤이어 휴먼 지네틱 테라피즈 인크. | Cftr mrna 조성물 및 관련 방법 및 사용 |
| BR112015022507A2 (pt) | 2013-03-14 | 2017-10-24 | Shire Human Genetic Therapies | ácidos ribonucleicos com nucleotídeos 4'-tio-modificados, composição compreendendo o mesmo e usos relacionados |
| EA201690576A1 (ru) | 2013-10-22 | 2016-10-31 | Шир Хьюман Дженетик Терапис, Инк. | Липидные композиции для доставки матричной рнк |
| PT3766916T (pt) * | 2014-06-25 | 2022-11-28 | Acuitas Therapeutics Inc | Novos lípidos e formulações de nanopartículas lipídicas para distribuição de ácidos nucleicos |
| JP6782171B2 (ja) | 2014-07-02 | 2020-11-11 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | メッセンジャーｒｎａのカプセル化 |
| WO2016011306A2 (fr) | 2014-07-17 | 2016-01-21 | Moderna Therapeutics, Inc. | Modifications de terminal de polynucléotides |
| EP3247363A4 (fr) * | 2015-01-21 | 2018-10-03 | Moderna Therapeutics, Inc. | Compositions de nanoparticules lipidiques |
| HUE057613T2 (hu) | 2015-09-17 | 2022-05-28 | Modernatx Inc | Vegyületek és készítmények terápiás szerek intracelluláris bejuttatására |
| JP2018531290A (ja) | 2015-10-22 | 2018-10-25 | モデルナティーエックス， インコーポレイテッド | 性感染症ワクチン |
| IL286515B2 (en) | 2015-10-28 | 2024-02-01 | Acuitas Therapeutics Inc | Novel lipids and nanoparticle formulations of lipids for delivery of nucleic acids |
| JP7065036B2 (ja) | 2015-12-17 | 2022-05-11 | モダーナティエックス・インコーポレイテッド | メチルマロニルＣｏＡムターゼをコードするポリヌクレオチド |
| WO2017153936A1 (fr) | 2016-03-10 | 2017-09-14 | Novartis Ag | Arn messager chimiquement modifié |
| US11078247B2 (en) | 2016-05-04 | 2021-08-03 | Curevac Ag | RNA encoding a therapeutic protein |
| WO2017201332A1 (fr) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucléotides codant pour l'acyl-coa déshydrogénase, à très longue chaîne pour le traitement de l'insuffisance en acyl-coa déshydrogénase à très longue chaîne |
| EP3458105B1 (fr) | 2016-05-18 | 2024-01-17 | Modernatx, Inc. | Polynucléotides codant pour la galactose-1-phosphate uridylyltransférase destinés au traitement de la galactosémie de type 1 |
| US10993918B2 (en) | 2016-05-18 | 2021-05-04 | Modernatx, Inc. | Polynucleotides encoding citrin for the treatment of Citrullinemia type 2 |
| MA45032A (fr) | 2016-05-18 | 2019-03-27 | Fundacion Para La Investig Medica Aplicada | Polynucléotides codant pour la porphobilinogène désaminase destinés au traitement de la porphyrie intermittente aiguë |
| MA45050A (fr) | 2016-05-18 | 2019-03-27 | Modernatx Inc | Polynucléotides codant pour la lipoprotéine lipase destinés au traitement de l'hyperlipidémie |
| MA46756A (fr) | 2016-11-10 | 2019-09-18 | Translate Bio Inc | Formulation de nanoparticules lipidiques à base de glace améliorée pour l'administration de l'arnm |
| EP3585417B1 (fr) | 2017-02-27 | 2023-02-22 | Translate Bio, Inc. | Méthode de préparation d'arnm cftr à codons optimisés |
| EP3398963B1 (fr) | 2017-05-04 | 2021-09-29 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Arnm chimiquement modifié pour une utilisation dans le traitement d'une maladie associée au gène cftr |
| WO2018213476A1 (fr) | 2017-05-16 | 2018-11-22 | Translate Bio, Inc. | Traitement de la fibrose kystique par administration d'arnm à codons optimisés codant pour la cftr |
| CN112638362A (zh) | 2018-07-23 | 2021-04-09 | 川斯勒佰尔公司 | 信使rna的干粉制剂 |
| MX2021005969A (es) | 2018-11-21 | 2021-09-14 | Translate Bio Inc | Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr nebulizado. |
| EP3908257A4 (fr) | 2019-01-08 | 2022-11-09 | Asklepios Biopharmaceutical, Inc. | Procédé de traitement de la fibrose kystique |
| WO2021021988A1 (fr) | 2019-07-30 | 2021-02-04 | Translate Bio, Inc. | Traitement de la fibrose kystique par administration d'arnm nébulisé codant pour la cftr |
| WO2021055609A1 (fr) | 2019-09-20 | 2021-03-25 | Translate Bio, Inc. | Arnm codant pour cftr modifiée |
| US20230210995A1 (en) | 2020-01-22 | 2023-07-06 | Cheung ANTHONY | Localized expression of therapeutic nucleic acids in lung epithelial cells |
| CN116096430A (zh) | 2020-04-27 | 2023-05-09 | 衣阿华大学研究基金会 | 用于治疗囊性纤维化的组合物和方法 |
| AU2021263590A1 (en) | 2020-05-01 | 2023-01-19 | Arcturus Therapeutics, Inc. | Nucleic acids and methods of treatment for cystic fibrosis |
| US20230181619A1 (en) | 2020-05-07 | 2023-06-15 | Translate Bio, Inc. | Improved compositions for cftr mrna therapy |
| EP4240326A1 (fr) | 2020-11-09 | 2023-09-13 | Translate Bio, Inc. | Compositions améliorées pour l'administration d'arnm à optimisation des codons |
| WO2022104131A1 (fr) | 2020-11-13 | 2022-05-19 | Modernatx, Inc. | Polynucléotides codant pour un régulateur de conductance transmembranaire de la mucoviscidose pour le traitement de la mucoviscidose |
-
2017
- 2017-05-18 EP EP17800209.3A patent/EP3458108A4/fr active Pending
- 2017-05-18 MA MA045053A patent/MA45053A/fr unknown
- 2017-05-18 US US16/302,370 patent/US11801227B2/en active Active
- 2017-05-18 WO PCT/US2017/033419 patent/WO2017201347A1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3458108A1 (fr) | 2019-03-27 |
| WO2017201347A1 (fr) | 2017-11-23 |
| US20190298658A1 (en) | 2019-10-03 |
| US11801227B2 (en) | 2023-10-31 |
| EP3458108A4 (fr) | 2020-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA45053A (fr) | Polynucléotides codant pour un régulateur de conductance transmembranaire de fibrose kystique pour le traitement de la fibrose kystique | |
| MA54649A (fr) | Modulateurs de régulateur de conductance transmembranaire de la fibrose kystique | |
| MA45032A (fr) | Polynucléotides codant pour la porphobilinogène désaminase destinés au traitement de la porphyrie intermittente aiguë | |
| MA45036A (fr) | Polynucléotides codant pour la citrine pour le traitement de la citrullinémie de type 2 | |
| IL261987B (en) | Modulators of transmembrane conductance regulation in cystic fibrosis | |
| MA49631A (fr) | Méthodes de traitement de la fibrose kystique | |
| IL275049A (en) | Processes for preparing modulators to regulate cystic fibrosis transmembrane conductance | |
| MA54105A (fr) | Méthodes de traitement de la fibrose kystique | |
| MA45050A (fr) | Polynucléotides codant pour la lipoprotéine lipase destinés au traitement de l'hyperlipidémie | |
| MA39748A (fr) | Cenicriviroc pour le traitement de la fibrose | |
| MA46788A (fr) | Traitement de la fibrose | |
| MA54227A (fr) | Méthodes de traitement de la fibrose kystique | |
| GB201713309D0 (en) | Determining available dynamic turing radius | |
| HK1243623A1 (zh) | 按摩器 | |
| BR112017014213A2 (pt) | moduladores de ciclopropanocarboxamida do regulador da condutância transmembrana da fibrose cística. | |
| IL274763A (en) | Methods for making cystic fibrosis transmembrane conductance modulator modulators | |
| GB2556425B (en) | Eccentric screw pump | |
| MA46099A (fr) | Composés pour le traitement de maladies associées à un dysfonctionnement mitochondrial | |
| MA50801A (fr) | Polynucléotides codant pour la phénylalanine hydroxylase pour le traitement de la phénylcétonurie | |
| RS62688B1 (sr) | Prenosivi uređaj za masažu | |
| FR3059015B1 (fr) | Appareil de repassage | |
| PL3449128T3 (pl) | Pompa śrubowa jednowirnikowa | |
| MA41094A (fr) | Procédés de traitement de troubles rénaux | |
| DE112017003245A5 (de) | Wellness-Pantolette mit skalierbarer Akupressurwirkung | |
| ITUB20160895A1 (it) | Macchina per il trattamento di pelli provvista di dispositivo di finitura |